Omeprazole
Prepared by: Abdulaziz M.shahbaz
omeprazole
• Generic name: omeprazole
• Brand names: PriLOSEC
• Dosage forms:
– Packet: 2.5mg , 10mg
– Suspension: 2mg/ml
– Tablet/capsule: 10mg, 20mg, 40mg
– Oral disintegrating tablets: 20mg
• Drug class: Proton pump inhibitors
• Rout of administration:
• Orally
• capsule
• Powder for oral suspension
• Intravenously , infusion
Mechanism of action
Omeprazole inhibits secretion of gastric acid
by irreversibly blocking the enzyme system of
hydrogen/potassium adenosine
triphosphatase, the “proton pump” of the
gastric parietal cell.
resulting in suppression of gastric acid
secretion
uses
1. Peptic ulcer
2. GERD
3. H pylori infection
4. NSAID induced ulcer
5. Reflux esophagitis
6. Zollinger-Ellison syndrome
7. Prophylaxis for ulcers
Uses
• GERD:
–<1 year: Safety and efficacy not established
–5-10 kg: 5 mg PO qDay
–10-20 kg: 10 mg PO qDay
–>20 kg: 20 mg PO qDay
Uses
• Erosive Esophagitis
• <1 month: Safety and efficacy not established
• Aged 1 month to <1 year
• 3 to <5 kg: 2.5 mg qDay
• 5 to <10 kg: 5 mg qDay
• ≥10 kg: 10 mg qDay
• May treat for up to 6 weeks
• Aged 1-16 years
• 5 to <10 kg: 5 mg PO qDay
• 10 to <20 kg: 10 mg PO qDay
• ≥20 kg: 20 mg PO qDay
• May treat for 4-8 weeks
Adverse Effects
• Headache (7%)
• Abdominal pain (5%)
• Diarrhea (4%)
• Nausea (4%)
• Vomiting (3%)
• Flatulence (3%)
• Dizziness (2%)
• Upper respiratory infection (2%)
• Acid regurgitation (2%)
• Constipation (2%)
• Rash (2%)
• Cough (1%)
Omeprazole

Omeprazole

  • 1.
  • 2.
    omeprazole • Generic name:omeprazole • Brand names: PriLOSEC • Dosage forms: – Packet: 2.5mg , 10mg – Suspension: 2mg/ml – Tablet/capsule: 10mg, 20mg, 40mg – Oral disintegrating tablets: 20mg • Drug class: Proton pump inhibitors • Rout of administration: • Orally • capsule • Powder for oral suspension • Intravenously , infusion
  • 3.
    Mechanism of action Omeprazoleinhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase, the “proton pump” of the gastric parietal cell. resulting in suppression of gastric acid secretion
  • 4.
    uses 1. Peptic ulcer 2.GERD 3. H pylori infection 4. NSAID induced ulcer 5. Reflux esophagitis 6. Zollinger-Ellison syndrome 7. Prophylaxis for ulcers
  • 5.
    Uses • GERD: –<1 year:Safety and efficacy not established –5-10 kg: 5 mg PO qDay –10-20 kg: 10 mg PO qDay –>20 kg: 20 mg PO qDay
  • 6.
    Uses • Erosive Esophagitis •<1 month: Safety and efficacy not established • Aged 1 month to <1 year • 3 to <5 kg: 2.5 mg qDay • 5 to <10 kg: 5 mg qDay • ≥10 kg: 10 mg qDay • May treat for up to 6 weeks • Aged 1-16 years • 5 to <10 kg: 5 mg PO qDay • 10 to <20 kg: 10 mg PO qDay • ≥20 kg: 20 mg PO qDay • May treat for 4-8 weeks
  • 7.
    Adverse Effects • Headache(7%) • Abdominal pain (5%) • Diarrhea (4%) • Nausea (4%) • Vomiting (3%) • Flatulence (3%) • Dizziness (2%) • Upper respiratory infection (2%) • Acid regurgitation (2%) • Constipation (2%) • Rash (2%) • Cough (1%)

Editor's Notes

  • #7 Indicated for treatment and to maintain healing of erosive esophagitis caused by acid-mediated GERD